WO2002085340A3 - Oligonucleotide compositions and their use to induce differentiation of cells - Google Patents

Oligonucleotide compositions and their use to induce differentiation of cells Download PDF

Info

Publication number
WO2002085340A3
WO2002085340A3 PCT/CA2002/000573 CA0200573W WO02085340A3 WO 2002085340 A3 WO2002085340 A3 WO 2002085340A3 CA 0200573 W CA0200573 W CA 0200573W WO 02085340 A3 WO02085340 A3 WO 02085340A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
seq
compositions
differentiation
induce differentiation
Prior art date
Application number
PCT/CA2002/000573
Other languages
French (fr)
Other versions
WO2002085340A2 (en
Inventor
Mario C Filion
Nigel C Phillips
Original Assignee
Bioniche Life Sciences Inc
Mario C Filion
Nigel C Phillips
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT02721915T priority Critical patent/ATE489467T1/en
Application filed by Bioniche Life Sciences Inc, Mario C Filion, Nigel C Phillips filed Critical Bioniche Life Sciences Inc
Priority to EP02721915A priority patent/EP1381375B1/en
Priority to IL15853402A priority patent/IL158534A0/en
Priority to CA002445071A priority patent/CA2445071A1/en
Priority to DE60238393T priority patent/DE60238393D1/en
Priority to MXPA03009761A priority patent/MXPA03009761A/en
Priority to NZ529160A priority patent/NZ529160A/en
Priority to JP2002582914A priority patent/JP4460220B2/en
Priority to KR1020037013799A priority patent/KR100913860B1/en
Priority to AU2002252891A priority patent/AU2002252891B2/en
Publication of WO2002085340A2 publication Critical patent/WO2002085340A2/en
Priority to IL158534A priority patent/IL158534A/en
Publication of WO2002085340A3 publication Critical patent/WO2002085340A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

The present invention provides compositions comprising a 3'-OH, 5'-OH, chemically unmodified, synthetic phosphodiester nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, and a pharmaceutically acceptable carrier, wherein the compositions are useful to induce differentiation of cells or to stimulate differentiation or production of pluripotent cells. The present invention provides methods of using these compositions to induce differentiation of pluripotent cells, including bone marrow derived cells, and to treat disease associated with insufficient differentiation of cells in animals and humans, including but not limited to leukemia, lymphoma, non-malignant blood disorders such as hemoglobinopathies, sickle cell disease, myelodysplastic syndrome, pancytopenia, anemia, thrombocytopenia and leukopenia.
PCT/CA2002/000573 2001-04-24 2002-04-23 Oligonucleotide compositions and their use to induce differentiation of cells WO2002085340A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
MXPA03009761A MXPA03009761A (en) 2001-04-24 2002-04-23 Oligonucleotide compositions and their use to induce differentiation of cells.
EP02721915A EP1381375B1 (en) 2001-04-24 2002-04-23 Oligonucleotide compositions and their use to induce differentiation of cells
IL15853402A IL158534A0 (en) 2001-04-24 2002-04-23 Oligonucletide compositions and their use to induce differentation of cells
CA002445071A CA2445071A1 (en) 2001-04-24 2002-04-23 Oligonucleotide compositions and their use to induce differentiation of cells
DE60238393T DE60238393D1 (en) 2001-04-24 2002-04-23 OLIGONUCLEOTIDE COMPOSITIONS AND ITS USE IN THE INDUCTION OF CELL DIFFERENTIATION
AT02721915T ATE489467T1 (en) 2001-04-24 2002-04-23 OLIGONUCLEOTIDE COMPOSITIONS AND USES THEREOF FOR INDUCING CELL DIFFERENTIATION
NZ529160A NZ529160A (en) 2001-04-24 2002-04-23 Oligonucleotide compositions and their use to induce differentiation of cells
AU2002252891A AU2002252891B2 (en) 2001-04-24 2002-04-23 Oligonucleotide compositions and their use to induce differentiation of cells
KR1020037013799A KR100913860B1 (en) 2001-04-24 2002-04-23 Oligonucleotide compositions and their use to induce differentiation of cells
JP2002582914A JP4460220B2 (en) 2001-04-24 2002-04-23 Oligonucleotide compositions and use of oligonucleotide compositions for inducing cell differentiation
IL158534A IL158534A (en) 2001-04-24 2003-10-21 Oligonucletide compositions and their use to induce differentiation of cells

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28615801P 2001-04-24 2001-04-24
US60/286,158 2001-04-24
US10/127,645 US7087586B2 (en) 2001-04-24 2002-04-22 Oligonucleotide compositions and their use to induce differentiation of cells
US10/127,645 2002-04-22

Publications (2)

Publication Number Publication Date
WO2002085340A2 WO2002085340A2 (en) 2002-10-31
WO2002085340A3 true WO2002085340A3 (en) 2003-10-30

Family

ID=26825829

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2002/000573 WO2002085340A2 (en) 2001-04-24 2002-04-23 Oligonucleotide compositions and their use to induce differentiation of cells

Country Status (12)

Country Link
US (2) US7087586B2 (en)
EP (1) EP1381375B1 (en)
JP (1) JP4460220B2 (en)
KR (1) KR100913860B1 (en)
AT (1) ATE489467T1 (en)
AU (1) AU2002252891B2 (en)
CA (1) CA2445071A1 (en)
DE (1) DE60238393D1 (en)
IL (2) IL158534A0 (en)
MX (1) MXPA03009761A (en)
NZ (1) NZ529160A (en)
WO (1) WO2002085340A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04002530A (en) * 2001-10-03 2004-05-31 Bioniche Life Sciences Inc Therapeutically useful triethyleneglycol cholesteryl oligonucleotides.
AU2003219383B2 (en) * 2002-04-22 2010-08-26 Bioniche Life Sciences Inc. Oligonucleotide compositions and their use for the modulation of immune responses
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
GB2443591B (en) * 2005-09-07 2010-04-28 Secr Defence Adjuvanted vaccine
EP2278979A4 (en) * 2008-05-21 2012-09-26 Us Gov Health & Human Serv Method of treating pneumoconiosis with oligodeoxynucleotides
US8053422B2 (en) * 2008-12-04 2011-11-08 The United States Of America As Represented By The Department Of Health And Human Services Anti-cancer oligodeoxynucleotides
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058118A2 (en) * 1998-05-14 1999-11-18 Cpg Immunopharmaceuticals Gmbh METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES
WO2001044465A2 (en) * 1999-12-13 2001-06-21 Bioniche Life Sciences Inc. Therapeutically useful synthetic oligonucleotides
WO2001047561A1 (en) * 1999-12-28 2001-07-05 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
WO2002018593A2 (en) * 2000-08-29 2002-03-07 Bioniche Life Sciences Inc. Modulation of fas and fasl expression
WO2003016567A2 (en) * 2001-08-17 2003-02-27 Bioniche Life Sciences Inc. Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567604A (en) * 1993-04-23 1996-10-22 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich oligonucleotides
US5866332A (en) * 1994-02-02 1999-02-02 Incyte Pharmaceuticals, Inc. Human myeloid terminal differentiation response gene
US5994320A (en) * 1995-02-06 1999-11-30 Regents Of The University Of Minnesota Antisense oligonucleotides and methods for treating central nervous system tumors
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US20020091095A1 (en) * 1999-12-13 2002-07-11 Phillips Nigel C. Modulation of Fas and FasL expression

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058118A2 (en) * 1998-05-14 1999-11-18 Cpg Immunopharmaceuticals Gmbh METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES
WO2001044465A2 (en) * 1999-12-13 2001-06-21 Bioniche Life Sciences Inc. Therapeutically useful synthetic oligonucleotides
WO2001047561A1 (en) * 1999-12-28 2001-07-05 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
WO2002018593A2 (en) * 2000-08-29 2002-03-07 Bioniche Life Sciences Inc. Modulation of fas and fasl expression
WO2003016567A2 (en) * 2001-08-17 2003-02-27 Bioniche Life Sciences Inc. Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FILION M C ET AL: "Development of short non-CpG phosphodiester oligonucleotides as immune stimulatory agents", VACCINE, vol. 21, no. 9-10, 2003, pages 983 - 989, XP004402627 *
FILION, MC ET AL.: "inhibition of cell cycle progression and induction of apoptosis in leukemia cells by Mycobacterium phlei DNA and derived synthetic oligonucleotides", PROCEEDINGS OF THE 11TH NCI.EORTC.AACR SYMPOSIUM ON NEW DRUGS IN CANCER THERAPY, 2000, XP002252541, Retrieved from the Internet <URL:www.aacr.org/newdrugs00/525.html> *
READER, S. ET AL.: "Identification of non-antisense phosphodiester oligonucleotides that induce cell cycle arrest and apoptosis in cancer cells", PROCEEDINGS OF THE 11TH NCI.EORTC.AACR SYMPOSIUM ON NEW DRUGS IN CANCER THERAPY, 2000, XP002252540, Retrieved from the Internet <URL:www.aacr.org/newdrugs00/526.html> *

Also Published As

Publication number Publication date
CA2445071A1 (en) 2002-10-31
KR100913860B1 (en) 2009-08-26
ATE489467T1 (en) 2010-12-15
AU2002252891B2 (en) 2007-09-20
KR20040047749A (en) 2004-06-05
DE60238393D1 (en) 2011-01-05
NZ529160A (en) 2006-06-30
US20070010472A1 (en) 2007-01-11
JP2004526775A (en) 2004-09-02
EP1381375B1 (en) 2010-11-24
MXPA03009761A (en) 2004-01-29
JP4460220B2 (en) 2010-05-12
IL158534A0 (en) 2004-05-12
EP1381375A2 (en) 2004-01-21
US20030045493A1 (en) 2003-03-06
US7087586B2 (en) 2006-08-08
WO2002085340A2 (en) 2002-10-31
IL158534A (en) 2010-06-16

Similar Documents

Publication Publication Date Title
DE69432375T2 (en) Antisense oligonucleotides for the treatment of immunosuppressive effects of TGF-beta2
WO2007031319A8 (en) Compositions comprising immunostimulatory rna oligonucleotides and methods for producing said rna oligonucleotides
EP1947184A3 (en) Delta-endotoxin genes and methods for their use
EP2186525A3 (en) G-CSF for use in the treatment of Parkinson&#39;s disease
WO2005021585A3 (en) Axmi-003, a delta-endotoxin gene and methods for its use
EP2671951A3 (en) Pesticidal genes from Brevibacillus and methods for their use
EP1340765A3 (en) Inverted chimeric and hybrid oligonucleotides
EP2455392A3 (en) A family of pesticidal proteins and methods for their use
NZ591416A (en) Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
WO2006083891A3 (en) Axmi-018, axmi-020, and axmi-021, a family of delta-endotoxin genes and methods for their use
CA2250682A1 (en) Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
EP2270188A3 (en) Defensin polynucleotides and methods of use
ATE300613T1 (en) HUMAN PHOSPHODIESTERASE SPECIFIC TO CYCLIC NUCLEOTIDES
WO2009052242A3 (en) Axmi-066 and axmi-076: delta-endotoxin proteins and methods for their use
WO2006107761A3 (en) Axmi-027, axmi-036 and axmi-038, a family of delta-endotoxin genes and methods for their use
WO2002085340A3 (en) Oligonucleotide compositions and their use to induce differentiation of cells
EP1036842A3 (en) Use of cyanobacterial fructose-1,6-bisphosphatase to improve growth of plants
HUP0300219A2 (en) Compositions and methods for l-nucleosides, l-nucleotides, and their analogs
WO2002064737A3 (en) Antisense modulation of protein phosphatase 2 catalytic subunit beta expression
WO2001031008A3 (en) Human and rat fgf-20 genes and gene expression products
WO2004027026A3 (en) Improved methods for preparing highly active april ligand polypeptides
MXPA02004782A (en) Sorghum dwarfing genes and methods of use.
WO2004046326A3 (en) Modulation of interleukin 22 receptor expression
WO2004013166A3 (en) S. aureus antigene
WO2004048531A3 (en) Modulation of death-associated protein kinase 1 expression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 158534

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2445071

Country of ref document: CA

Ref document number: 1020037013799

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002252891

Country of ref document: AU

Ref document number: 2002582914

Country of ref document: JP

Ref document number: PA/a/2003/009761

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 529160

Country of ref document: NZ

Ref document number: 2002721915

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002721915

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642